[go: up one dir, main page]

NO992960L - Substituerte nitrogen-inneholdende heterocykliske forbindelser som inhibitorer for p38 protein-kinase - Google Patents

Substituerte nitrogen-inneholdende heterocykliske forbindelser som inhibitorer for p38 protein-kinase

Info

Publication number
NO992960L
NO992960L NO992960A NO992960A NO992960L NO 992960 L NO992960 L NO 992960L NO 992960 A NO992960 A NO 992960A NO 992960 A NO992960 A NO 992960A NO 992960 L NO992960 L NO 992960L
Authority
NO
Norway
Prior art keywords
inhibitors
protein kinase
containing heterocyclic
heterocyclic compounds
substituted nitrogen
Prior art date
Application number
NO992960A
Other languages
English (en)
Other versions
NO992960D0 (no
NO315047B1 (no
Inventor
Guy W Bemis
Francesco Gerald Salituro
John Patrick Duffy
John E Cochran
Edmund Martin Harrington
Mark A Murcko
Keith P Wilson
Michael Su
Vincent P Galullo
Original Assignee
Vertex Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/822,373 external-priority patent/US5945418A/en
Application filed by Vertex Pharma filed Critical Vertex Pharma
Publication of NO992960D0 publication Critical patent/NO992960D0/no
Publication of NO992960L publication Critical patent/NO992960L/no
Publication of NO315047B1 publication Critical patent/NO315047B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/70—Sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/56—Amides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/18—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/12—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/20—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Biochemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
NO19992960A 1996-12-18 1999-06-17 Substituerte nitrogen-inneholdende heterocykliske forbindelser som inhibitorer for p38 protein-kinase NO315047B1 (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US3428896P 1996-12-18 1996-12-18
US08/822,373 US5945418A (en) 1996-12-18 1997-03-20 Inhibitors of p38
US08/862,925 US6147080A (en) 1996-12-18 1997-06-10 Inhibitors of p38
PCT/US1997/023392 WO1998027098A1 (en) 1996-12-18 1997-12-17 SUBSTITUTED NITROGEN CONTAINING HETEROCYCLES AS INHIBITORS OF p38 PROTEIN KINASE

Publications (3)

Publication Number Publication Date
NO992960D0 NO992960D0 (no) 1999-06-17
NO992960L true NO992960L (no) 1999-08-17
NO315047B1 NO315047B1 (no) 2003-06-30

Family

ID=27364615

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19992960A NO315047B1 (no) 1996-12-18 1999-06-17 Substituerte nitrogen-inneholdende heterocykliske forbindelser som inhibitorer for p38 protein-kinase

Country Status (28)

Country Link
US (1) US6147080A (no)
EP (1) EP0951467B1 (no)
JP (1) JP4171072B2 (no)
CN (2) CN1153770C (no)
AP (1) AP1136A (no)
AT (1) ATE236165T1 (no)
AU (1) AU738000B2 (no)
BG (1) BG64533B1 (no)
BR (1) BR9714415A (no)
CA (1) CA2274825C (no)
CZ (1) CZ299600B6 (no)
DE (1) DE69720522T2 (no)
DK (1) DK0951467T3 (no)
EA (1) EA002855B1 (no)
EE (1) EE04191B1 (no)
ES (1) ES2202658T3 (no)
HU (1) HUP0001125A3 (no)
ID (1) ID21919A (no)
IL (1) IL130349A0 (no)
IS (1) IS5069A (no)
NO (1) NO315047B1 (no)
NZ (1) NZ336146A (no)
PL (1) PL202464B1 (no)
PT (1) PT951467E (no)
SK (1) SK284578B6 (no)
TR (1) TR199902194T2 (no)
TW (1) TW521071B (no)
WO (1) WO1998027098A1 (no)

Families Citing this family (126)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7091181B2 (en) 1994-12-12 2006-08-15 Omeros Corporation Method of inhibition of pain and inflammation during surgery comprising administration of soluble TNF receptors
US6608060B1 (en) * 1996-12-18 2003-08-19 Vertex Pharmaceuticals Incorporated Inhibitors of p38
JP2001520170A (ja) 1997-10-16 2001-10-30 ボード・オヴ・リージェンツ，ザ・ユニヴァーシティ・オヴ・テキサス・システム Ｎｆ−ａｔ３機能に関連した心肥大動物モデルと治療法
EP1037639A4 (en) 1997-12-19 2002-04-17 Smithkline Beecham Corp HETEROARYL-SUBSTITUTED IMIDAZOLE COMPOUNDS, THEIR PHARMACEUTICAL COMPOSITIONS AND USES
MY132496A (en) 1998-05-11 2007-10-31 Vertex Pharma Inhibitors of p38
WO1999061039A2 (en) * 1998-05-22 1999-12-02 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Novel composition for modulating ischemic cell death
US6858617B2 (en) 1998-05-26 2005-02-22 Smithkline Beecham Corporation Substituted imidazole compounds
EP1277740A1 (en) * 1998-06-12 2003-01-22 Vertex Pharmaceuticals Incorporated Inhibitors of p38
JP2002517486A (ja) 1998-06-12 2002-06-18 バーテックス ファーマシューティカルズ インコーポレイテッド ｐ３８のインヒビター
US6184226B1 (en) 1998-08-28 2001-02-06 Scios Inc. Quinazoline derivatives as inhibitors of P-38 α
AR023659A1 (es) 1998-09-18 2002-09-04 Vertex Pharma Un compuesto inhibidor de p38, una composicion farmaceutica que lo comprende y el uso de dicha composicion en el tratamiento y prevencion de estados patologicos
WO2000017175A1 (en) * 1998-09-18 2000-03-30 Vertex Pharmaceuticals Incorporated INHIBITORS OF p38
EP1261334A1 (en) * 1998-10-20 2002-12-04 Omeros Corporation Irrigation solution containing mapk inhibitors and their use for treating pain and inflammation
JP2002528506A (ja) 1998-11-04 2002-09-03 スミスクライン・ビーチャム・コーポレイション ピリジン−４−イルまたはピリミジン−４−イル置換ピラジン
UA73492C2 (en) 1999-01-19 2005-08-15 Aromatic heterocyclic compounds as antiinflammatory agents
JP2002537397A (ja) 1999-02-22 2002-11-05 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド 抗炎症剤としての多環ヘテロ環式誘導体
WO2000055152A1 (en) 1999-03-12 2000-09-21 Boehringer Ingelheim Pharmaceuticals, Inc. Aromatic heterocyclic compounds as anti-inflammatory agents
CN1156452C (zh) 1999-03-12 2004-07-07 贝林格尔·英格海姆药物公司 作为消炎剂的化合物
JP2000281588A (ja) * 1999-03-30 2000-10-10 Sankyo Co Ltd ガンの予防又は治療薬及びそのスクリーニング方法
ATE323482T1 (de) * 1999-07-02 2006-05-15 Stuart A Lipton Verwendung von p38 mapk inhibitoren in der behandlung von augenkrankheiten
WO2001004115A2 (en) 1999-07-09 2001-01-18 Boehringer Ingelheim Pharmaceuticals, Inc. Novel process for synthesis of heteroaryl-substituted urea compounds
KR100537241B1 (ko) * 1999-10-21 2005-12-19 에프. 호프만-라 로슈 아게 Ｐ38 단백질 키나제의 억제제로서의 알킬아미노 치환된이중고리 질소 헤테로고리 화합물
WO2001029042A1 (en) * 1999-10-21 2001-04-26 F. Hoffmann-La Roche Ag Heteroalkylamino-substituted bicyclic nitrogen heterocycles as inhibitors of p38 protein kinase
AU1783201A (en) 1999-11-23 2001-06-04 Smithkline Beecham Corporation 3,4-dihydro-(1h)quinazolin-2-one compounds as csbp/p38 kinase inhibitors
AU1782301A (en) 1999-11-23 2001-06-04 Smithkline Beecham Corporation 3,4-dihydro-(1h)quinazolin-2-one compounds as csbp/p39 kinase inhibitors
US6759410B1 (en) 1999-11-23 2004-07-06 Smithline Beecham Corporation 3,4-dihydro-(1H)-quinazolin-2-ones and their use as CSBP/p38 kinase inhibitors
US6525046B1 (en) 2000-01-18 2003-02-25 Boehringer Ingelheim Pharmaceuticals, Inc. Aromatic heterocyclic compounds as antiinflammatory agents
US6608052B2 (en) 2000-02-16 2003-08-19 Boehringer Ingelheim Pharmaceuticals, Inc. Compounds useful as anti-inflammatory agents
US7235551B2 (en) 2000-03-02 2007-06-26 Smithkline Beecham Corporation 1,5-disubstituted-3,4-dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases
MXPA02009319A (es) * 2000-03-22 2003-03-12 Vertex Pharma Inhibidores de p38.
WO2002014281A1 (en) * 2000-08-11 2002-02-21 Vertex Pharmaceuticals Incorporated Pyridine derivatives as inhibitors of p38
PE20020506A1 (es) * 2000-08-22 2002-07-09 Glaxo Group Ltd Derivados de pirazol fusionados como inhibidores de la proteina cinasa
US7998507B2 (en) * 2000-09-21 2011-08-16 Elan Pharma International Ltd. Nanoparticulate compositions of mitogen-activated protein (MAP) kinase inhibitors
CN1847229B (zh) 2000-10-23 2011-05-04 史密丝克莱恩比彻姆公司 2，4，8-三取代-8H-吡啶并[2，3-d]嘧啶-7-酮化合物
US6670357B2 (en) * 2000-11-17 2003-12-30 Bristol-Myers Squibb Company Methods of treating p38 kinase-associated conditions and pyrrolotriazine compounds useful as kinase inhibitors
US6867300B2 (en) * 2000-11-17 2005-03-15 Bristol-Myers Squibb Company Methods for the preparation of pyrrolotriazine compounds useful as kinase inhibitors
WO2002058695A1 (en) * 2000-12-20 2002-08-01 Merck & Co., Inc. (halo-benzo carbonyl)heterocyclo fused phenyl p38 kinase inhibiting agents
CN100376571C (zh) * 2001-02-12 2008-03-26 霍夫曼-拉罗奇有限公司 6-取代的吡啶并嘧啶类化合物
GB0112348D0 (en) * 2001-05-19 2001-07-11 Smithkline Beecham Plc Compounds
GB2375771A (en) * 2001-05-24 2002-11-27 Univ Leeds Decellularisation of tissue implant material
ATE415162T1 (de) * 2001-06-11 2008-12-15 Vertex Pharma Isochinolin-inhibitoren von p38
US20030066998A1 (en) 2001-08-02 2003-04-10 Lee Howard Wing Hoon Quantum dots of Group IV semiconductor materials
US6710366B1 (en) 2001-08-02 2004-03-23 Ultradots, Inc. Nanocomposite materials with engineered properties
US6819845B2 (en) 2001-08-02 2004-11-16 Ultradots, Inc. Optical devices with engineered nonlinear nanocomposite materials
US6794265B2 (en) 2001-08-02 2004-09-21 Ultradots, Inc. Methods of forming quantum dots of Group IV semiconductor materials
US7005669B1 (en) 2001-08-02 2006-02-28 Ultradots, Inc. Quantum dots, nanocomposite materials with quantum dots, devices with quantum dots, and related fabrication methods
GB0124939D0 (en) * 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
GB0124931D0 (en) * 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
GB0124941D0 (en) * 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
GB0124938D0 (en) * 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
GB0124934D0 (en) * 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
GB0124932D0 (en) * 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
GB0124936D0 (en) * 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
GB0124933D0 (en) * 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
EP1476840A4 (en) * 2002-01-11 2007-05-09 Vertex Pharma CRYSTALLINE STRUCTURES OF JNK INHIBITION COMPLEXES AND BINDING POCKETS THEREOF
JP2005519895A (ja) * 2002-01-18 2005-07-07 ファルマシア・コーポレーション Ｐ３８阻害剤としての置換ピリダジノン
EP2258687B1 (en) * 2002-02-12 2012-12-26 Glaxosmithkline LLC Nicotinamide derivates useful as P38 inhibitors
DE60319066T2 (de) 2002-02-25 2009-02-26 Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield 1,4-disubstituierte benzokondensierte cycloalkyl-harnstoffverbindungen zur behandlung von zytokinvermittelten erkrankungen
MXPA04009352A (es) * 2002-04-18 2005-01-25 Pharmacia Corp Terapia de combinacion para el tratamiento de la enfermedad de parkinson con inhibidores de ciclooxigenasa-2 (cox2).
EP1499320B1 (en) 2002-04-19 2007-08-22 Smithkline Beecham Corporation Novel compounds
AU2003231034B2 (en) * 2002-04-23 2009-03-05 Bristol-Myers Squibb Company Pyrrolo-triazine aniline compounds useful as kinase inhibitors
US7388009B2 (en) * 2002-04-23 2008-06-17 Bristol-Myers Squibb Company Heteroaryl-substituted pyrrolo-triazine compounds useful as kinase inhibitors
TW200306841A (en) * 2002-04-23 2003-12-01 Bristol Myers Squibb Co Aryl ketone pyrrolo-triazine compounds useful as kinase inhibitors
TW200400034A (en) * 2002-05-20 2004-01-01 Bristol Myers Squibb Co Pyrazolo-pyrimidine aniline compounds useful as kinase inhibitors
NZ537155A (en) * 2002-05-23 2006-09-29 Cytopia Pty Ltd Protein kinase inhibitors
ES2278170T3 (es) 2002-07-09 2007-08-01 BOEHRINGER INGELHEIM PHARMA GMBH & CO.KG Composiciones farmaceuticas de anticolinergicos e inhibidores de la quinasa p38 en el tratamiento de enfermedades respiratorias.
GB0217757D0 (en) 2002-07-31 2002-09-11 Glaxo Group Ltd Novel compounds
WO2004050023A2 (en) 2002-11-27 2004-06-17 Dmi Biosciences, Inc. Treatment of diseases and conditions mediated by increased phosphorylation
GB0308186D0 (en) * 2003-04-09 2003-05-14 Smithkline Beecham Corp Novel compounds
GB0308201D0 (en) * 2003-04-09 2003-05-14 Smithkline Beecham Corp Novel compounds
GB0308185D0 (en) * 2003-04-09 2003-05-14 Smithkline Beecham Corp Novel compounds
ATE482200T1 (de) * 2003-05-01 2010-10-15 Bristol Myers Squibb Co Als kinaseinhibitoren geeignete arylsubstituierte pyrazolamidverbindungen
EP2251343A1 (en) 2003-05-15 2010-11-17 Arqule, Inc. Imidazothiazoles as p38-kinase-inhibitors
CA2528438A1 (en) * 2003-06-03 2005-01-06 Novartis Ag P-38 inhibitors
PL1641764T3 (pl) 2003-06-26 2011-12-30 Novartis Ag Inhibitory kinazy P38 na bazie 5-członowych heterocykli
WO2005007632A1 (en) * 2003-07-18 2005-01-27 Pharmacia Corporation Substituted pyridazinones as inhibitors of p38
CN101337944A (zh) 2003-07-25 2009-01-07 诺瓦提斯公司 p38激酶抑制剂
GB0318814D0 (en) * 2003-08-11 2003-09-10 Smithkline Beecham Corp Novel compounds
US7419978B2 (en) * 2003-10-22 2008-09-02 Bristol-Myers Squibb Company Phenyl-aniline substituted bicyclic compounds useful as kinase inhibitors
CN102127056B (zh) 2003-12-03 2013-08-21 Ym生物科学澳大利亚私人有限公司 微管蛋白抑制剂
GB0402143D0 (en) * 2004-01-30 2004-03-03 Smithkline Beecham Corp Novel compounds
WO2006010082A1 (en) 2004-07-08 2006-01-26 Arqule, Inc. 1,4-disubstituted naphtalenes as inhibitors of p38 map kinase
US7504521B2 (en) * 2004-08-05 2009-03-17 Bristol-Myers Squibb Co. Methods for the preparation of pyrrolotriazine compounds
US20060035893A1 (en) 2004-08-07 2006-02-16 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders
PE20060421A1 (es) 2004-08-12 2006-06-01 Bristol Myers Squibb Co Procedimiento para preparar un compuesto de pirrolotriazina anilina como inhibidores de cinasa
WO2006021848A1 (en) * 2004-08-27 2006-03-02 Ranbaxy Laboratories Limited Anti-inflammatory agents
US20080051416A1 (en) * 2004-10-05 2008-02-28 Smithkline Beecham Corporation Novel Compounds
CA2584368A1 (en) 2004-10-19 2006-04-27 Arqule, Inc. Synthesis of imidazooxazole and imidazothiazole inhibitors of p38 map kinase
PE20060777A1 (es) 2004-12-24 2006-10-06 Boehringer Ingelheim Int Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
US20060178388A1 (en) * 2005-02-04 2006-08-10 Wrobleski Stephen T Phenyl-substituted pyrimidine compounds useful as kinase inhibitors
PE20061193A1 (es) 2005-03-25 2006-12-02 Glaxo Group Ltd DERIVADOS DE 3,4-DIHIDROPIRIMIDO[4,5-d]PIRIMIDIN-2-[1H]-0NA COMO INHIBIDORES DE QUINASA p38
UY29440A1 (es) 2005-03-25 2006-10-02 Glaxo Group Ltd Nuevos compuestos
EP1868612A4 (en) 2005-03-25 2010-03-24 Glaxo Group Ltd NOVEL CONNECTIONS
CN101495475A (zh) 2005-03-25 2009-07-29 葛兰素集团有限公司 制备吡啶并[2,3-d]嘧啶-7-酮和3,4-二氢嘧啶并[4,5-d]嘧啶-2(1H)-酮衍生物的方法
US20060235020A1 (en) * 2005-04-18 2006-10-19 Soojin Kim Process for preparing salts of 4-[[5-[(cyclopropylamino)carbonyl]-2-methylphenyl]amino]-5-methyl-N-propylpyrrolo[2,1-f][1,2,4]triazine-6-carboxamide and novel stable forms produced therein
GB0512429D0 (en) * 2005-06-17 2005-07-27 Smithkline Beecham Corp Novel compound
US7473784B2 (en) * 2005-08-01 2009-01-06 Bristol-Myers Squibb Company Benzothiazole and azabenzothiazole compounds useful as kinase inhibitors
CN101273039A (zh) * 2005-08-12 2008-09-24 默克公司 可用作p38激酶抑制剂的杂二环化合物
BRPI0617948A2 (pt) 2005-10-28 2011-08-09 Takeda Pharmaceutical composto, pró-droga de um composto, agente farmacêutico, método para inibir uma metaloproteinase de matriz, e, uso de um composto
KR20080107408A (ko) * 2006-03-07 2008-12-10 브리스톨-마이어스 스큅 컴퍼니 키나제 억제제로서 유용한 피롤로트리아진 아닐린 전구약물화합물
EP2468717B1 (en) 2006-10-27 2013-11-20 Bristol-Myers Squibb Company Heterocyclic Amide Compounds Useful as Kinase Inhibitors
US7943617B2 (en) 2006-11-27 2011-05-17 Bristol-Myers Squibb Company Heterobicyclic compounds useful as kinase inhibitors
EP2131858A4 (en) * 2007-03-20 2011-11-23 Cadila Pharmaceuticals Ltd P38 INHIBITORS
EP1992344A1 (en) 2007-05-18 2008-11-19 Institut Curie P38 alpha as a therapeutic target in pathologies linked to FGFR3 mutation
EP2108641A1 (en) * 2008-04-11 2009-10-14 Laboratorios Almirall, S.A. New substituted spiro[cycloalkyl-1,3'-indo]-2'(1'H)-one derivatives and their use as p38 mitogen-activated kinase inhibitors
EP2111861A1 (en) 2008-04-21 2009-10-28 Ranbaxy Laboratories Limited Compositions of phosphodiesterase type IV inhibitors
WO2009155389A1 (en) * 2008-06-20 2009-12-23 Bristol-Myers Squibb Company Triazolopyridine compounds useful as kinase inhibitors
US8338604B2 (en) 2008-06-20 2012-12-25 Bristol-Myers Squibb Company Imidazopyridine and imidazopyrazine compounds useful as kinase inhibitors
WO2010038428A1 (ja) * 2008-09-30 2010-04-08 武田薬品工業株式会社 タキサン系抗がん剤の置き換え薬
US8450363B2 (en) 2009-02-06 2013-05-28 Elan Pharmaceuticals, Inc. Inhibitors of Jun N-terminal kinase
GB0902648D0 (en) 2009-02-17 2009-04-01 Argenta Discovery Ltd Pharmaceutical compounds and compositions
GB0908317D0 (en) * 2009-05-14 2009-06-24 Argenta Discovery Ltd Pharmaceutical compounds and compositions
WO2012031057A1 (en) 2010-09-01 2012-03-08 Bristol-Myers Squibb Company Bms- 582949 for the treatment of resistant rheumatic disease
EP2707369B1 (en) * 2011-05-09 2016-07-27 Eip Pharma, LLC Compositions and methods for treating alzheimer's disease
EP3553169B1 (en) 2011-12-28 2021-11-03 Kyoto Prefectural Public University Corporation Normalization of culture of corneal endothelial cells
CN103772392A (zh) * 2012-10-23 2014-05-07 杨子娇 一类治疗房角狭窄的化合物及其用途
JP6730701B2 (ja) 2013-11-14 2020-07-29 学校法人同志社 細胞増殖促進または細胞障害抑制による角膜内皮治療薬
US9579322B2 (en) 2014-07-09 2017-02-28 Eip Pharma, Llc Methods for treating neurologic disorders
DK3368052T3 (da) 2015-10-27 2022-03-14 Childrens Hospital Med Ct Anvendelse af mapk-hæmmere for at nedbringe tabet af hæmatopoietiske stamceller under ex vivo-dyrkning og -genmanipulation
US20190060286A1 (en) 2016-02-29 2019-02-28 University Of Florida Research Foundation, Incorpo Chemotherapeutic Methods
WO2019056003A1 (en) 2017-09-18 2019-03-21 Eip Pharma, Llc CO-CRYSTALS FROM NEFLAMAPIMOD (VX -745)
KR20200067170A (ko) 2017-10-05 2020-06-11 풀크럼 쎄러퓨틱스, 인코포레이티드 FSHD의 치료를 위하여 DUX4 및 하류 유전자 발현을 저감시키는 p38 키나제 저해제
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
SMT202200134T1 (it) 2018-03-08 2022-05-12 Incyte Corp Composti di amminopirazindiolo come inibitori di pi3k-y
US11046658B2 (en) 2018-07-02 2021-06-29 Incyte Corporation Aminopyrazine derivatives as PI3K-γ inhibitors
JP2022509271A (ja) * 2018-11-30 2022-01-20 シャンハイ ファーマシューティカルズ ホールディング カンパニー，リミティド 窒素含有ヘテロシクリル系化合物及びその組成物、製造方法並びに使用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5716972A (en) * 1993-01-13 1998-02-10 Smithkline Beecham Corporation Pyridyl substituted imidazoles
IL110296A (en) * 1993-07-16 1999-12-31 Smithkline Beecham Corp Imidazole compounds process for their preparation and pharmaceutical compositions containing them
AU6691994A (en) * 1994-02-10 1995-08-29 Vladimir Ivanovich Ivanov Device for phono-electrophoresis
US5559137A (en) * 1994-05-16 1996-09-24 Smithkline Beecham Corp. Compounds
CA2210322A1 (en) * 1995-01-12 1996-07-18 Smithkline Beecham Corporation Novel compounds
US5717100A (en) * 1995-10-06 1998-02-10 Merck & Co., Inc. Substituted imidazoles having anti-cancer and cytokine inhibitory activity
ATE433446T1 (de) * 1995-10-06 2009-06-15 Merck & Co Inc Substituierte imidazole mit krebsremmender und cytokininhibierender wirkung
GB9523675D0 (en) * 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
ZA97175B (en) * 1996-01-11 1997-11-04 Smithkline Beecham Corp Novel substituted imidazole compounds.
WO1997044467A1 (en) * 1996-05-20 1997-11-27 Signal Pharmaceuticals, Inc. MITOGEN-ACTIVATED PROTEIN KINASE p38-2 AND METHODS OF USE THEREFOR
EP0906307B1 (en) * 1996-06-10 2005-04-27 Merck & Co., Inc. Substituted imidazoles having cytokine inhibitory activity
GB9613021D0 (en) * 1996-06-21 1996-08-28 Pharmacia Spa Bicyclic 4-aralkylaminopyrimidine derivatives as tyrosine kinase inhibitors
WO1998002430A1 (en) * 1996-07-11 1998-01-22 Pfizer Pharmaceuticals Inc. Pyridylpyrrole compounds useful as interleukin- and tnf antagonists
WO1998006715A1 (en) * 1996-08-09 1998-02-19 Smithkline Beecham Corporation Novel piperazine containing compounds
US5945418A (en) * 1996-12-18 1999-08-31 Vertex Pharmaceuticals Incorporated Inhibitors of p38

Also Published As

Publication number Publication date
AP1136A (en) 2003-01-31
DE69720522T2 (de) 2003-11-27
EP0951467A1 (en) 1999-10-27
WO1998027098A1 (en) 1998-06-25
TW521071B (en) 2003-02-21
ID21919A (id) 1999-08-12
ES2202658T3 (es) 2004-04-01
CA2274825C (en) 2008-08-26
PT951467E (pt) 2003-08-29
CZ216399A3 (cs) 1999-09-15
IS5069A (is) 1999-06-07
DE69720522D1 (de) 2003-05-08
ATE236165T1 (de) 2003-04-15
AU5610598A (en) 1998-07-15
EE9900252A (et) 1999-12-15
EA199900559A1 (ru) 2000-02-28
CN1244867A (zh) 2000-02-16
NO992960D0 (no) 1999-06-17
TR199902194T2 (xx) 2000-06-21
CN1519240A (zh) 2004-08-11
CA2274825A1 (en) 1998-06-25
SK80599A3 (en) 2000-01-18
EP0951467B1 (en) 2003-04-02
BR9714415A (pt) 2000-04-18
CN1153770C (zh) 2004-06-16
PL334133A1 (en) 2000-02-14
NO315047B1 (no) 2003-06-30
US6147080A (en) 2000-11-14
NZ336146A (en) 2000-09-29
BG103575A (en) 2000-06-30
CN1284783C (zh) 2006-11-15
CZ299600B6 (cs) 2008-09-17
HUP0001125A3 (en) 2002-01-28
DK0951467T3 (da) 2003-07-21
EE04191B1 (et) 2003-12-15
AU738000B2 (en) 2001-09-06
JP4171072B2 (ja) 2008-10-22
SK284578B6 (sk) 2005-07-01
PL202464B1 (pl) 2009-06-30
EA002855B1 (ru) 2002-10-31
HK1023340A1 (en) 2000-09-08
JP2001506266A (ja) 2001-05-15
HUP0001125A2 (hu) 2000-10-28
BG64533B1 (bg) 2005-06-30
IL130349A0 (en) 2000-06-01
AP9901565A0 (en) 1999-06-30

Similar Documents

Publication Publication Date Title
NO992960D0 (no) Substituerte nitrogen-inneholdende heterocykliske forbindelser som inhibitorer for p38 protein-kinase
DK0912559T3 (da) Kondenserede heterocykliske forbindelser som proteintyrosinkinaseinhibitorer
NO20021783D0 (no) Alkylamino-substituerte bicykliske nitrogen-heterocykler som inhibitorer for P38-protein-kinase
NO20021781D0 (no) Heteroalkylamino-substituerte bicykliske nitrogenheterocykler som inhibitorer for P38-proteinkinase
NO990123D0 (no) Bicykliske heteroaromatiske forbindelser som protein-tyrosin-kinase-inhibitorer
NO990124D0 (no) Bicykliske heteroaromatiske forbindelser som protein-tyrosin-kinase-inhibitorer
DK1460072T3 (da) Bicykliske heteroaromatiske forbindelser som proteintyrosinkinaseinhibitorer
EE200000289A (et) Asendatud 4-amino-tiasool-2-üüli ühendid kui tsükliinisõltuvusega kinaaside inhibiitorid
EE9900527A (et) Substitueeritud pürasoolid kui p38 kinaasi inhibiitorid
NO960393D0 (no) Heterosykliske fenylforbindelser som COX-2-inhibitorer
DK1318997T3 (da) Pyrazolforbindelser der er nyttige som proteinkinase-inhibitorer
DK1345922T3 (da) Pyrazolforbindelser der er nyttige som proteinkinaseinhibitorer
DE69940115D1 (de) Heterocyclische inhibitoren von p38
DK1500657T3 (da) Substituerede pyrazoler som p38-kinaseinhibitorer
LTPA2014028I1 (lt) Pakeistieji 3-cianochinolinai kaip proteintirozinkinazės inhibitoriai
NO20011575D0 (no) Substituerte 3-cyanokinoliner som proteintyrosin-kinase- inhibitorer
DE60005684D1 (de) Purin-derivative inhibitoren der tyrosi-protein kinase syk
DK1475377T3 (da) Indol-derivater og deres anvendelse som inhibitorer for phosphodiesterase 4
DK1100797T3 (da) Heterocycliske forbindelser som inhibitorer af rotamaseenzymer
DE69711020D1 (de) Thiazole derivate als protein kinase c inhibitoren
DK1060178T3 (da) Heterocyklisk forbindelser som inhibitorer af rotamase enzymer
NO20012832D0 (no) Heterocykliske karboksamid-holdige tiourea-inhibitorer for herpesvirus inneholdende fenylendiamingruppe
DK1317448T3 (da) Pyrazolforbindelser der er nyttige som proteinkinaseinhibitorer
SI0951467T1 (en) SUBSTITUTED NITROGEN CONTAINING HETEROCYCLES AS INHIBITORS OF p38 PROTEIN KINASE

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees